Five leaders in the medical innovation field released a white paper
today titled The New Role of Academia in Drug Discovery and Development:
New Thinking, New Competencies, New Results. This white paper reflects
key recommendations from a July 2010 town hall meeting in Kansas City
hosted by Friends of Cancer Research, Kansas Bioscience Authority, The
University of Kansas Cancer Center, Ewing Marion Kauffman Foundation and
Council for American Medical Innovation.
The white paper outlines how government, nonprofit organizations and
academic institutions can define new models of working with the private
sector to enhance drug development efforts and bring safer, more
effective drugs to the market more efficiently. Recommendations for this
new model are based on a series of expert panel discussions held during
the town hall meeting.
"This call to action is the result of an extraordinary meeting of key
policy makers, academics, industry leaders and the non-profit community,
who understand the urgency for new collaborations in cancer research
and drug development," said Roy A. Jensen, M.D., director of The
University of Kansas Cancer Center. "As universities increasingly seek
to commercialize their research, we need a new paradigm for drug
discovery. The University of Kansas Cancer Center is proud to partner
with these organizations to lead the way."
"Together, we can knock down barriers to scientific innovation, and, as
we do that, we will accelerate our progress in the fight against
diseases such as cancer," said Tom Thornton, president and CEO of the
Kansas Bioscience Authority.
"We hope our nation's healthcare leaders and policymakers will study the
insights and adopt the recommendations in this report. We can make
groundbreaking progress in how scientific discoveries translate to
patient healthcare if they do," said Lesa Mitchell, vice president of
advancing innovation at the Kauffman Foundation.
"This white paper outlines critical steps toward much-needed increased
interagency collaboration," said Dr. Ellen Sigal, Chair, Friends of
Cancer Research. "The proposals discussed within this document aim to
accelerate the process to help get scientific breakthroughs to patients.
The message is clear; without collaboration among all agencies and
academic centers, the full potential of biomedical research may be
"The Council for American Medical Innovation is pleased to have
supported this ground breaking event examining the new role of academia
in drug development," said Debra Lappin, President of the Council for
American Medical Innovation. "The white paper reflects a rare dialogue
among leaders across sectors and paves the way forward for the next
generation of research, discovery and medical advances."